TY - JOUR
T1 - Resting energy expenditure in Gaucher's disease type 1
T2 - Effect of Gaucher's cell burden on energy requirements
AU - Barton, Donald J.
AU - Ludman, Mark D.
AU - Benkov, Keith
AU - Grabowski, Gregory A.
AU - LeLeiko, Neal S.
N1 - Funding Information:
Supported by grants from the Heckscher Foundation for Children, a General Clinical Research Center grant from the National Institutes of Health (NIH) Division of Research Resources (RR-71). the NIH (ROI-DK26729). the March of Dimes Birth Defects Foundation (l-857). the UJAjFederation of Jewish Philanthropies, the National Gaucher Foundation (NGF no. 19). and a grant from Florence and Theodore Baumritter to the Mount Sinai Center for Jewish Genetic Diseases. Gregory A. Grabowski is the recipient of an NIH Research Career Development Award (KOQ-DKOI3 51) and an Irma T. Hirsch1 Career Scientist Award. Mark D. Ludman is the recipient of a General Clinical Research Center Clinical Associate Physician Award (RR00071-25Sl).
PY - 1989/12
Y1 - 1989/12
N2 - The resting energy expenditure (REE; kcal/d) or 25 patients with Gaucher's disease type 1 was determined by indirect calorimetry. The average observed REE for the group was approximately 44% greater (P < .01) than that predicted (predicted REE) for these patient's age, sex, height, and weight. The increased caloric requirements of these patients was manifested by a height-for-age less than or equal to the fifth percentile in seven of nine growing children and a muscle mass of less than the fifth percentile in 15 of 19 patients studied. The excess REE (observed REE - predicted REE) for individual Gaucher's disease type 1 patients was directly related to their liver volume as estimated from radionuclide scans and to the mass of the spleen as measured at splenectomy. The relationship between spleen mass and excess REE was demonstrated by an average 22.0% decrease in REE following splenectomy in five patients. Based on these data, the metabolic rate of the splenic tissue removed from the patients was calculated to be 96.8 kcal/d/kg, about twofold to threefold less than that of normal splenic tissue. These findings indicate that the elevated REE observed in these patients resulted from the large mass of Gaucher's cells, which although individually hypometabolic, were cumulatively an excessive metabolic burden. Furthermore, they suggest that indirect calorimetry may be a quantitative tool for measuring disease progression and the effect of therapeutic intervention in Gaucher's disease type 1.
AB - The resting energy expenditure (REE; kcal/d) or 25 patients with Gaucher's disease type 1 was determined by indirect calorimetry. The average observed REE for the group was approximately 44% greater (P < .01) than that predicted (predicted REE) for these patient's age, sex, height, and weight. The increased caloric requirements of these patients was manifested by a height-for-age less than or equal to the fifth percentile in seven of nine growing children and a muscle mass of less than the fifth percentile in 15 of 19 patients studied. The excess REE (observed REE - predicted REE) for individual Gaucher's disease type 1 patients was directly related to their liver volume as estimated from radionuclide scans and to the mass of the spleen as measured at splenectomy. The relationship between spleen mass and excess REE was demonstrated by an average 22.0% decrease in REE following splenectomy in five patients. Based on these data, the metabolic rate of the splenic tissue removed from the patients was calculated to be 96.8 kcal/d/kg, about twofold to threefold less than that of normal splenic tissue. These findings indicate that the elevated REE observed in these patients resulted from the large mass of Gaucher's cells, which although individually hypometabolic, were cumulatively an excessive metabolic burden. Furthermore, they suggest that indirect calorimetry may be a quantitative tool for measuring disease progression and the effect of therapeutic intervention in Gaucher's disease type 1.
UR - https://www.scopus.com/pages/publications/0024789707
U2 - 10.1016/0026-0495(89)90165-0
DO - 10.1016/0026-0495(89)90165-0
M3 - Article
C2 - 2593834
AN - SCOPUS:0024789707
SN - 0026-0495
VL - 38
SP - 1238
EP - 1243
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 12
ER -